<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878474</url>
  </required_header>
  <id_info>
    <org_study_id>TA-8995-01</org_study_id>
    <nct_id>NCT01878474</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, First Time-in-humans Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Escalating Doses of TA-8995 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of single doses of TA-8995&#xD;
      in healthy Caucasian and Japanese volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests (haematology, biochemistry and urinalysis)</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs (supine systolic and diastolic blood pressure, heart rate and body temperature)</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak concentration (ng/mL) of TA-8995</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of peak concentration (hr) of TA-8995</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (mg/L・hr) up to 24 h (AUC0-24), 72 h (AUC0-72), 168 h (AUC0-168), 336 h (AUC0-336) and infinity (AUC0-∞) of TA-8995</measure>
    <time_frame>336 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Cholesterol Ester Transfer Protein (CETP) activity (%) and concentration (mg/mL)</measure>
    <time_frame>336 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Single ascending dose in Caucasian men</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Age-effect in Caucasian men</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gender-effect in Caucasian women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending dose in Japanese men</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Single ascending dose in Caucasian men</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Age-effect in Caucasian men</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placeo: Gender-effect in Caucasian women</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Single ascending dose in Japanese men</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg</description>
    <arm_group_label>Single ascending dose in Caucasian men</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>Drug: TA-8995 25 mg</description>
    <arm_group_label>Age-effect in Caucasian men</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>Drug: TA-8995 25 mg</description>
    <arm_group_label>Gender-effect in Caucasian women</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-8995</intervention_name>
    <description>Drug: TA-8995 25, 50, 100 and 150 mg</description>
    <arm_group_label>Single ascending dose in Japanese men</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single ascending dose in Caucasian men</description>
    <arm_group_label>Placebo: Single ascending dose in Caucasian men</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Age-effect in Caucasian men</description>
    <arm_group_label>Placebo: Age-effect in Caucasian men</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gender-effect in Caucasian women</description>
    <arm_group_label>Placeo: Gender-effect in Caucasian women</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single ascending dose in Japanese men</description>
    <arm_group_label>Placebo: Single ascending dose in Japanese men</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian men aged 18-55 years and ≥65 years&#xD;
&#xD;
          -  Women of non-childbearing potential&#xD;
&#xD;
          -  Japanese men aged 18-55 years&#xD;
&#xD;
          -  Subjects were deemed healthy on the basis of medical history, physical examination,&#xD;
             Electrocardiogram (ECG), vital signs and safety tests of blood and urine&#xD;
&#xD;
          -  Subjects were able to give fully informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HDL-C level ≥2.59 mmol/L&#xD;
&#xD;
          -  Abnormal Holter ECG&#xD;
&#xD;
          -  Family history of long QT syndrome, hypokalaemia or Torsade de Pointes&#xD;
&#xD;
          -  Vital signs or 12-lead ECG values outside the acceptable range&#xD;
&#xD;
          -  Positive tests for hepatitis B and C, HIV 1 and 2&#xD;
&#xD;
          -  Positive urine pregnancy test (women only)&#xD;
&#xD;
          -  Severe adverse reaction or allergy to any drug&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Smoking within the 6 months before dosing with TA-8995 (Caucasian subjects), or&#xD;
             smoking more than 10 cigarettes daily (Japanese subjects)&#xD;
&#xD;
          -  Over-the-counter or prescribed medication up to 7 days or 5 half-lives (whichever was&#xD;
             longer) before dosing with TA-8995&#xD;
&#xD;
          -  Consuming food or drinks containing grapefruit or cranberry within the 7 days before&#xD;
             dosing&#xD;
&#xD;
          -  Participation in other clinical trials, or loss of more than 450 mL blood within the&#xD;
             previous 3 months&#xD;
&#xD;
          -  Clinically relevant abnormal findings at the screening assessment&#xD;
&#xD;
          -  Clinically relevant abnormal medical history or concurrent medical condition&#xD;
&#xD;
          -  Possibility that volunteer would not cooperate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Warrington, MA MD FRCP FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>June 12, 2013</last_update_submitted>
  <last_update_submitted_qc>June 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MT-8995</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Cholesteryl ester transfer proteins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

